Skip to main content
AmigoFish

Clinical Pharmacology Podcast with Nathan Teuscher

Nathan TeuscherAudio

Format:
Podcast
New episodes:
Monthly
Typical length:
about 25 minutes
Latest episode:
Not rated yet
CosmosOpen at the sourceReport a problemIs this your show? Get a badge

About this show

I discuss clinical pharmacology and pharmacometrics topics from the perspective of drug development scientists. I share my expertise and knowledge about designing and conducting clinical pharmacology studies and discuss how to analyze the data using the most effective approaches. I draw from my experience of over 20 years working in drug development organizations and consultancies.

Covers: clinical pharmacology, pharmacometrics, drug development, population pharmacokinetics, model-informed drug development, bioequivalence, clinical data standards, pharmacokinetic modeling

Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

This podcast explains clinical pharmacology and pharmacometrics for drug development, from the viewpoint of a scientist with over two decades in industry and consulting. Recent episodes cover inter-occasion variability, exposure-response modeling, renal and hepatic impairment, and bioequivalence statistics.

Report a problem with this summary

Cosmos

Similar by topic and creator

See the full Cosmos

Similar shows

See all Science shows

Explore more

Episodes

  • Project Optimus (Ep. 21)

    · 39 min

    Today’s episode was about Project Optimus, the FDA initiative to improve dose selection and optimization for oncology products. Julie Bullock was a guest on this episode and shared her expertise as a former oncology clinical pharmacology reviewer at the FDA and as a current consultant in the pharmaceutical industry. Links discussed in the show: - Project Optimus FDA (https://go.teuschersolutions.com/projectoptimus) - List of FDA (https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus) guidances and publications for Project Optimus - May 2022 FDA-ASCO workshop: Getting the Dose Right: Optimizing Dose Selection Strategies in Oncology (https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/getting-dose-right-optimizing-dose-selection-strategies-oncology-fda-asco-virtual-workshop-05032022) - Sept 2023 Second Annual FDA ASCO WORKSHOP on Getting the Dosage Right (https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/second-annual-fda-asco-workshop-getting-dosage-right-september-6-7-2023-09062023) (this one focused on combinations) - Feb 2024 FDA/AACR Public Workshop: Optimizing Dosages for Oncology Drugs (https://www.aacr.org/professionals/policy-and-advocacy/regulatory-science-and-policy/events/fda-aacr-workshop-optimizing-dosages-for-oncology-drug-products/) - You can connect with Julie on LinkedIn (https://www.linkedin.com/in/julie-bullock-ba6826/) - You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message - Send me a message (https://go.teuschersolutions.com/contact) - Sign up for my newsletter (https://go.teuschersolutions.com/newsletter) Copyright Teuscher Solutions LLC All Rights Reserved

    Not rated yet
  • Tackling TMDD Models (Ep. 20)

    · 15 min

    Today’s show is about TMDD or target-mediated drug disposition models. I review the scientific and physiologic basis for TMDD models, how to review data and determine if a TMDD model is needed. I review the various modeling approaches along with my recommendations for specific TMDD models. I hope this information helps you understand how to recognize TMDD behaviors and the options for modeling that data. Links discussed in the show: - A tutorial on target-mediated drug disposition (TMDD) models (https://go.teuschersolutions.com/tmdd1) - Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification (https://go.teuschersolutions.com/tmdd2) - You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message - Send me a message (https://go.teuschersolutions.com/contact) - Sign up for my newsletter (https://go.teuschersolutions.com/newsletter) Copyright Teuscher Solutions LLC All Rights Reserved

    Not rated yet
  • Communication for scientists (Ep. 19)

    · 46 min

    Today’s episode is about communication for scientists. I believe that improvements in communication skills can have a greater impact on your career and work than technical skills. Michael Piperno, an expert in communication and leadership skills joins me to discuss communication challenges and solutions for clinical pharmacologists and pharmacometricians. Links discussed in the show: You can connect with Michael - On his website (https://www.wearecomvia.com/) - On LinkedIn (https://www.linkedin.com/in/michaelpiperno/) - On his blog (https://www.wearecomvia.com/blog/) - On his podcast (https://www.wearecomvia.com/podcast/) - Subscribe to Michael’s newsletter (https://www.wearecomvia.com/subscribe/) - View upcoming leadership and communication workshops (https://www.wearecomvia.com/workshops/) You can connect with me - You can connect with me on ⁠LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message⁠⁠ - Send me a message (https://go.teuschersolutions.com/contact)⁠⁠ - Sign up for my newsletter⁠ (https://go.teuschersolutions.com/newsletter) Copyright Teuscher Solutions LLC All Rights Reserved

    Not rated yet
  • Cell Therapy and Clinical Pharmacology (Ep. 18)

    · 13 min

    Today’s episode is about cell therapies, including CAR T-cell theraphy for cancer. I give an overview of cell therapy and the challenges of clinical pharmacology in this new area of research. Links discussed in the show: CAR T-cell Therapy Image (https://go.teuschersolutions.com/cart) You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message Send me a message (https://go.teuschersolutions.com/contact) Sign up for my newsletter (https://go.teuschersolutions.com/newsletter) Copyright Teuscher Solutions LLC All Rights Reserved

    Not rated yet
  • Allometry in Pediatrics and First in Human Studies (Ep. 17)

    · 17 min

    Happy New Year! Today’s episode is all about allometric scaling in pharmacokinetic and pharmacodynamics. In particular, I’ll discuss how to use it for scaling from adults to pediatrics and for selection of first in human doses. Links discussed in the show: - Boxenbaum manuscript (https://go.teuschersolutions.com/boxenbaum1982) - FDA guidance on First in Human doses (https://go.teuschersolutions.com/fda-fih) - You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message - Send me a message (https://go.teuschersolutions.com/contact) - Sign up for my newsletter (https://go.teuschersolutions.com/newsletter) Copyright Teuscher Solutions LLC All Rights Reserved

    Not rated yet
  • Computer System Validation for Pharmacometrics (Ep. 16)

    · 30 min

    This is the last podcast for 2023. Thank you for listening throughout the year! In today’s episode I talk about computer system validation for pharmacometrics. I review my experience with validation in multiple companies over 20 years and discuss what auditors and FDA inspectors want to see. Links discussed in the show: - Computer system validation guidance for medical devices (https://go.teuschersolutions.com/computersystemvalidation-1) - Computer systems used in clinical trials (https://go.teuschersolutions.com/computersystemvalidation-2) - Computer system assurance guidance for medical devices (https://go.teuschersolutions.com/computersystemvalidation-3) - EMA guidance on computer systems and electronic data in clinical trials (https://go.teuschersolutions.com/computersystemvalidation-4) - You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message - Send me a message (https://go.teuschersolutions.com/contact) - Sign up for my newsletter (https://go.teuschersolutions.com/newsletter) Copyright Teuscher Solutions LLC All Rights Reserved

    Not rated yet
  • QSP, PBPK, PKPD, PopPK … analysis abbreviation soup! (Ep. 15)

    · 26 min

    In today’s episode I cover 4 different modeling approaches: QSP, PBPK, PopPK, and PKPD. All of these are methods for analyzing data to predict either drug concentrations, or a response variable. But each method is developed in a different way and has different assumptions and limitations. Links discussed in the show: - You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message - Send me a message (https://go.teuschersolutions.com/contact) - Sign up for my newsletter (https://go.teuschersolutions.com/newsletter) Copyright Teuscher Solutions LLC All Rights Reserved

    Not rated yet
  • Handling BLQ samples (Ep. 13)

    · 22 min

    In today’s episode I discuss BLQ handing for both non-compartmental and modeling analysis approaches. I discuss how BLQ samples are defined, methods for analyzing them, and situations when you should use different analysis approaches. Links discussed in the show: - FDA guidance on bioanalytical method validation (https://go.teuschersolutions.com/bioa-method-val) - ICH M10 guidance on bioanalytical method validation (https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation-scientific-guideline) - Handling data below the limit of quantitation in mixed effects models (https://go.teuschersolutions.com/handling-blq-1) - Ways to fit a PK model with some data below the quantification limit (https://go.teuschersolutions.com/handling-blq-2) - You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message - Send me a message (https://go.teuschersolutions.com/contact) - Sign up for my newsletter (https://go.teuschersolutions.com/newsletter) Copyright Teuscher Solutions LLC All Rights Reserved

    Not rated yet
  • Clinical Drug Interaction Studies (Ep. 14)

    · 19 min

    In today’s episode I covered the different types of drug interactions, followed by features of clinical drug evaluation studies recommended in the guidance. Then I will review recommendations for both stand-alone clinical drug interaction studies, as well as nested drug interaction studies. I’ll finish with recommended approaches for interpreting drug interaction study results and expressing that information in drug labeling. Links discussed in the show: - Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis by Delara et al. (https://go.teuschersolutions.com/polypharmacy) - FDA guidance on clinical drug interactions (https://go.teuschersolutions.com/clinical-ddi) - FDA guidance on in vitro drug interactions (https://go.teuschersolutions.com/nonclinical-ddi) - FDA guidance on therapeutic protein drug interactions (https://go.teuschersolutions.com/protein-ddi) - EMA guideline on drug interactions (https://go.teuschersolutions.com/ema-ddi) - You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message - Send me a message (https://go.teuschersolutions.com/contact) - Sign up for my newsletter (https://go.teuschersolutions.com/newsletter) Copyright Teuscher Solutions LLC All Rights Reserved

    Not rated yet
  • PK in patients with impaired renal function (Ep. 12)

    · 14 min

    In today’s episode I discuss the evaluation of pharmacokinetics in patients with impaired renal function. I include information from both the US FDA and EMA guidance documents linked below. I discuss the determination of when a dedicated renal impairment study is needed, characteristics of the study design and how to analyze and interpret the results. Links discussed in the show: • FDA guidance (https://go.teuschersolutions.com/fda-renal) on PK in patients with impaired renal function • EMA guidance (https://go.teuschersolutions.com/ema-renal) on Evaluation of PK in patients with decreased renal function • You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message. • Send me a message (https://go.teuschersolutions.com/contact) • Sign up for my newsletter (https://go.teuschersolutions.com/newsletter) Copyright Teuscher Solutions LLC All Rights Reserved

    Not rated yet